HIVワクチン市場：抗体別、タイプ別、カテゴリー別-2023～2030年の世界予測

HIVワクチンの世界市場は、2023年にはCAGR 39.55%で6億7,783万米ドルと予測され、2030年には70億1,184万米ドルと驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のHIVワクチン市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.HIVワクチンの世界市場規模および予測は？

2.予測期間中、世界のHIVワクチン市場を形成するCOVID-19の阻害要因と影響は？

3.HIVワクチンの世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.HIVワクチンの世界市場における競争戦略は？

5.HIVワクチンの世界市場における技術動向と規制の枠組みは？

6.HIVワクチンの世界市場における主要ベンダーの市場シェアは？

7.HIVワクチンの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • HIVワクチン生産への投資の増加
    • 世界のHIVの蔓延
    • HIV予防プログラムによる意識の向上
  • 抑制要因
    • HIV薬剤耐性に関する問題
  • 機会
    • HIV治療薬の手頃な価格の上昇
    • HIVワクチン臨床試験の研究開発活動の増加
  • 課題
    • HIVワクチン商品化の限界
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ
  • HIVワクチン構築方法論
    • 弱毒生ワクチン
    • 合成ペプチドワクチン
    • 不活化ワクチン
    • DNAワクチン
    • 組換えベクターワクチン
  • HIVワクチンの商品化
    • 制御された送信
    • 効能
    • 再発
    • 経済的
    • 製造のスケーラビリティ
  • HIVワクチンの臨床試験
    • フェーズI
    • フェーズII
    • フェーズIII
  • 薬物ワクチン接種の分類
    • ヌクレオシド類似体逆転写酵素阻害剤
    • 非ヌクレオシド系逆転写酵素阻害剤
    • プロテアーゼ阻害剤
    • 融合阻害剤

第6章 HIVワクチン市場：抗体別

• イントロダクション
• ジクロキサシリン
• フシジン酸軟膏
• ゲンタマイシン軟膏
• ムピロシン軟膏

第7章 HIVワクチン市場：タイプ別

• イントロダクション
• 急性爪囲炎
• カンジダ性爪囲炎
• 慢性爪囲炎
• 化膿性爪囲炎

第8章 HIVワクチン市場：カテゴリー別

• イントロダクション
• 予防ワクチン
• 治療ワクチン

第9章 南北アメリカのHIVワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のHIVワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのHIVワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. HIV VACCINES MARKET SIZE, 2022 VS 2030
• FIGURE 3. HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2022 VS 2030 (%)
• FIGURE 5. HIV VACCINES MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 6. HIV VACCINES MARKET SIZE, BY CATEGORY, 2022 VS 2030 (%)
• FIGURE 7. HIV VACCINES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. HIV VACCINES MARKET DYNAMICS
• FIGURE 9. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. HIV VACCINES MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. HIV VACCINES MARKET SIZE, BY CATEGORY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 5. HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 10. HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 15. HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 27. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 28. CANADA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 44. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 45. CHINA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 47. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 48. INDIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 99. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 100. ITALY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 111. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 112. POLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 114. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 115. QATAR HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
• TABLE 144. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 145. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 146. HIV VACCINES MARKET LICENSE & PRICING

The Global HIV Vaccines Market is forecasted to grow significantly, with a projected USD 677.83 million in 2023 at a CAGR of 39.55% and expected to reach a staggering USD 7,011.84 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global HIV Vaccines Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global HIV Vaccines Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Antibodies, market is studied across Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, and Mupirocin Ointment. The Fusidic Acid Ointment is projected to witness significant market share during forecast period.

Based on Type, market is studied across Acute Paronychia, Candidal Paronychia, Chronic Paronychia, and Pyogenic Paronychia. The Acute Paronychia is projected to witness significant market share during forecast period.

Based on Category, market is studied across Preventive Vaccines and Therapeutic Vaccines. The Preventive Vaccines is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global HIV Vaccines Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global HIV Vaccines Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global HIV Vaccines Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global HIV Vaccines Market?

4. What is the competitive strategic window for opportunities in the Global HIV Vaccines Market?

5. What are the technology trends and regulatory frameworks in the Global HIV Vaccines Market?

6. What is the market share of the leading vendors in the Global HIV Vaccines Market?

7. What modes and strategic moves are considered suitable for entering the Global HIV Vaccines Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. HIV Vaccines Market, by Antibodies, 2022 vs 2030
• 4.3. HIV Vaccines Market, by Type, 2022 vs 2030
• 4.4. HIV Vaccines Market, by Category, 2022 vs 2030
• 4.5. HIV Vaccines Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising investments for HIV vaccine production
    • 5.1.1.2. Prevalence of HIV worldwide
    • 5.1.1.3. Increasing awareness due to HIV prevention programs
  • 5.1.2. Restraints
    • 5.1.2.1. Issues related to HIV drug resistance
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising affordability of HIV medicines
    • 5.1.3.2. Increasing R&D activities for HIV vaccines clinical trials
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations of commercialization of HIV vaccine
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization
  • 5.9.1. HIV vaccine construct methodologies
    • 5.9.1.1. Live Attenuated Vaccine
    • 5.9.1.2. Synthetic Peptide Vaccines
    • 5.9.1.3. Inactivated Vaccines
    • 5.9.1.4. DNA Vaccine
    • 5.9.1.5. Recombinant Vector Vaccine
  • 5.9.2. Commercialization of HIV vaccines
    • 5.9.2.1. Controlled Transmission
    • 5.9.2.2. Efficacy
    • 5.9.2.3. Relapse
    • 5.9.2.4. Economical
    • 5.9.2.5. Manufacturing Scalability
  • 5.9.3. HIV vaccine clinical trials
    • 5.9.3.1. Phase I
    • 5.9.3.2. Phase II
    • 5.9.3.3. Phase III
  • 5.9.4. Drug vaccination categorization
    • 5.9.4.1. Nucleoside Analogue Reverse Transcriptase Inhibitors
    • 5.9.4.2. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 5.9.4.3. Protease Inhibitors
    • 5.9.4.4. Fusion Inhibitors

6. HIV Vaccines Market, by Antibodies

• 6.1. Introduction
• 6.2. Dicloxacillin
• 6.3. Fusidic Acid Ointment
• 6.4. Gentamicin Ointment
• 6.5. Mupirocin Ointment

7. HIV Vaccines Market, by Type

• 7.1. Introduction
• 7.2. Acute Paronychia
• 7.3. Candidal Paronychia
• 7.4. Chronic Paronychia
• 7.5. Pyogenic Paronychia

8. HIV Vaccines Market, by Category

• 8.1. Introduction
• 8.2. Preventive Vaccines
• 8.3. Therapeutic Vaccines

9. Americas HIV Vaccines Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific HIV Vaccines Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa HIV Vaccines Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing